[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
about
Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
P2860
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@en
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@nl
type
label
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@en
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@nl
prefLabel
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@en
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@nl
P2093
P2860
P1476
[How to make the choice in the ...... tching to a second EGFR-TKI?].
@en
P2093
Chuanhao Tang
Haifeng Qin
Hongjun Gao
Jianjie Li
Wanfeng Guo
Weixia Wang
Xiaoqing Liu
Xiaoyan Li
P2860
P304
P356
10.3779/J.ISSN.1009-3419.2013.07.03
P407
P577
2013-07-01T00:00:00Z